Apollo Therapeutics, a biopharmaceutical company originally set up by three UK universities (Cambridge, Imperial College London and University College London) and three pharmaceutical companies (AstraZeneca, GSK and Johnson & Johnson Innovation), has secured $226.5 million venture capital financing.